A preclinical study argues for dual targeting of 17β-HSD10 and CDK5/p25 as a disease-modifying approach in Alzheimer’s disease. The report links 17β-HSD10-dependent mitochondrial impairment and tau-mediated neurodegeneration to the CDK5 pathway, positioning the combined strategy as complementary rather than redundant across the two mechanisms.